Phase II randomized multi-center trial of total neoadjuvant therapy with and without CD40 agonist, APX005M, for locally advanced rectal adenocarcinoma
The purpose of the study is to determine if giving chemoradiation with APX005M, the study drug, before surgery will result in any response in rectal cancer. We are hoping to find out how well this treatment works.
Locally Advanced Rectal Cancer
-At least 18 years of age
-Stage II, III, or IV rectal cancer
- No prior treatment for rectal adenocarcinoma
-Prior radiation therapy to pelvis
-Any active known or suspected autoimmune disease
18 - 120
Healthy Volunteers Needed
Duration of Participation
Approximately 3 months of treatment and up to 36 months in follow-up.
Knight Clinical Trials Information Line
University of Texas Southwestern Medical Center